Doctors in metropolitan hospitals that treat patients with COVID ‑ 19 have received the option of additional medication protection to reduce the risk of infection and the severity of the disease. They can take part in the study of a cure for malaria as a prophylactic for COVID-19.
This is a hydroxychloroquine medicine. They treat malaria, arthritis, lupus erythematosus, asthma. This is the same medicine that the president of the United States, Donald Trump, recently advertised on the entire planet, saying on Twitter that the drug showed promising results in the treatment of COVID-19 and that it will be available to Americans. The medicine was actually used during the SARS epidemic in 2002-2003, and it was tested in Wuhan. At the same time, experts, including representatives of the drug manufacturing company, warn: there is indeed information about the positive effect of the drug in patients with a new coronavirus infection, but its effectiveness has not yet been proven, since there have not yet been full-scale studies carried out according to all the rules. Now such studies are just beginning.
“WHO has announced the launch of the Solidarity international clinical trial to evaluate several drugs for the treatment of COVID ‑ 19, including hydroxychloroquine. A clinical study of Discovery is also being conducted in Europe, which includes a group of its use. Thousands of patients from different countries are planned to be included in this study. Belgium, the Netherlands, the United Kingdom, Germany, Spain, and France, ”said Yuri Molchanov, Sanofi’s Corporate Relations Director for Eurasia, WG. This company, as confirmed by “RG” in the DSM Group, is the main supplier of the drug to Russia.
If you follow the rules, if the drug is not registered for the treatment of a particular disease, you can not use it. But during a pandemic, and even when there are no specific means with proven effectiveness against a new infection, and people need to be protected and saved, it’s no longer a matter of severe restrictions.
Perhaps that is why Moscow doctors were invited to take part in studies on the use of the medicine – on the initiative of the city health department.
When there are no drugs with proven effectiveness, but people need to be rescued, there are no longer any severe restrictions
According to the RG, in the contact center established in connection with the study, it is assumed that the project will primarily include the medical staff of the hospitals receiving patients with COVID ‑ 19. Doctors who declare participation and have no contraindications to the drug will receive it for free for two weeks. Clearly, under the control of well-being. Participants who find contraindications will not take the medicine and will make up a control group to evaluate the effectiveness of the drug.
“Particular attention should be paid to protecting medical workers who are at increased risk of contracting a new coronavirus infection. In China, as of early March, 3,300 health workers were infected, and according to local media, at least 22 people died by the end of February. In Italy 20 percent of health workers are infected.
The goal of this open, controlled study is to determine the efficacy and safety of hydroxychloroquine as a preventative measure for the development of COVID-19 symptoms in healthcare providers who treat and care for COVID-19 patients, “says a resource created for online registration of doctors who want to participate in the study.
– .
